Precigen Inc (PGEN)
Healthcare
Biotechnology
6.50 $
-1.2%
vs. previous close
Closing price · As of: 4. Aug 2026
All figures as a percentage of total assets in the same period.
| Tick rows to compare them in a chart (up to 4) | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 30.3% | 33.0% | 33.2% | 18.2% | 39.9% | 51.5% | 47.3% | 43.5% | 54.7% | 45.5% | 70.5% | 73.6% | |
| 4.8% | 13.8% | 6.6% | 8.0% | 14.3% | 14.4% | 16.5% | 10.1% | 2.2% | 5.0% | 20.3% | 19.3% | |
| 20.1% | 24.3% | 25.0% | 9.4% | 31.1% | 16.5% | 31.8% | 30.2% | 25.9% | 41.6% | 67.4% | 62.5% | |
| 5.1% | 5.3% | 4.5% | 4.7% | 3.7% | 5.8% | 6.5% | 0.6% | 6.4% | 1.0% | 0.8% | 2.8% | |
| 4.5% | 2.7% | 2.2% | 2.4% | 3.0% | 3.5% | 3.6% | 0.1% | 0.1% | 0.0% | 0.0% | 6.1% | |
| 6.6% | 4.4% | 6.8% | 13.3% | 18.0% | 13.4% | 11.1% | 12.6% | 3.4% | – | – | – | |
| 17.5% | 16.8% | 16.6% | 18.1% | 20.9% | 14.0% | 17.3% | 10.4% | 17.1% | 17.6% | 13.2% | 9.7% | |
| 11.4% | 25.2% | 23.8% | 27.5% | 18.1% | 15.0% | 20.8% | 14.5% | 20.6% | 26.9% | 3.1% | 2.0% | |
| 29.0% | 28.2% | 40.0% | 35.5% | 47.1% | 84.3% | 78.6% | 70.2% | 41.5% | 21.5% | 73.5% | 86.6% | |
| 8.2% | 7.7% | 10.0% | 9.5% | 8.6% | 27.0% | 13.4% | 9.6% | 36.4% | 15.2% | 14.8% | 23.8% | |
| 0.7% | 0.2% | 0.1% | 0.1% | 0.1% | 7.9% | 1.0% | 0.4% | 20.6% | 0.8% | 0.7% | 0.7% | |
| 1.1% | 0.5% | 0.9% | 1.0% | 1.7% | 1.2% | 1.5% | 0.9% | 1.9% | 1.1% | 2.4% | 7.7% | |
| 1.5% | 0.8% | 0.8% | 0.9% | 29.5% | 40.9% | 54.5% | 50.8% | – | – | – | 59.5% | |
| 66.8% | 70.7% | 59.0% | 63.0% | 50.7% | 15.7% | 21.4% | 29.8% | 58.5% | 78.5% | 26.5% | 13.4% | |
| -79.5% | -55.3% | -76.8% | -100.1% | -185.8% | -362.7% | -579.6% | -532.3% | -865.2% | -1,300.6% | -1,439.2% | -1,494.9% | |
| 17.2% | 11.3% | 12.4% | 14.2% | 18.1% | 33.8% | 53.1% | 55.0% | 92.8% | 161.9% | 184.3% | 194.6% |
Data as of: August 4, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.